CORONA Remedies Limited (CORONA)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 3 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹2,105.7

🎯 Key Takeaways

CORONA Remedies Limited is in a phase of sustained growth driven by product portfolio expansion and geographic reach, particularly in women's healthcare, cardio-diabetes, pain management, and urology segments. The company has strengthened its brand portfolio, achieving an #27 ranking in IPM and expanding power brands from 3 to 8 since 2023, while maintaining a 34.
⚠️ Revenue concentration risk persists, with 76% of revenue derived from just 32 brands, making the company vulnerable to product-specific demand shifts

Market Cap

₹10,870

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About CORONA 📊 Interactive Charts

📖 The Story

CORONA Remedies Limited is in a phase of sustained growth driven by product portfolio expansion and geographic reach, particularly in women's healthcare, cardio-diabetes, pain management, and urology segments. The company has strengthened its brand portfolio, achieving an #27 ranking in IPM and expanding power brands from 3 to 8 since 2023, while maintaining a 34.80% covered market share. Strategic focus on chronic care, biosimilars, and international markets is supported by EU-GMP and WHO-GMP certified facilities with 1.65 billion annual capacity. Despite concentration risks in revenue and geography, the company demonstrates financial resilience with high ROCE (40.79%) and ROE (29.16%), underpinned by operational efficiency and disciplined capital allocation.

📰 What's Happening

In Q1 FY27, CORONA Remedies scheduled an earnings conference call for August 3, 2026, to discuss unaudited results for the quarter ended June 30, 2026, with management representation including the Managing Director, Joint Managing Director, and CFO. The audio recording of the call was made available post-event on the company's website, ensuring transparency in disclosures. Additionally, the company conducted its 22nd Annual General Meeting on July 9, 2026, via video conference, where all resolutions — including adoption of audited financials, declaration of a final dividend of ₹10 per share, and appointments of directors and auditors — were unanimously approved. Shareholders were required to update KYC details to receive dividends electronically, reflecting compliance with regulatory and governance norms.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has emphasized strategic focus on chronic care, biosimilars, and international expansion as pillars of future growth, backed by certified manufacturing infrastructure and a diversified brand portfolio. The company maintains a disciplined approach to capital allocation, prioritizing organic growth, capacity optimization, and shareholder returns, as evidenced by the consistent recommendation of dividends and reinvestment in high-potential therapeutic areas. While specific forward guidance was not detailed in the latest filings, the continued emphasis on product innovation and geographic reach signals confidence in sustained top-line expansion.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Revenue concentration risk persists, with 76% of revenue derived from just 32 brands, making the company vulnerable to product-specific demand shifts or regulatory setbacks. 2. Geographic dependency on the West Zone, contributing 45.20% of revenue, exposes the company to regional economic or policy fluctuations. 3. Despite margin expansion, pricing pressures in competitive therapeutic segments could challenge profitability if cost control slips. 4. International expansion plans may face execution risks, including regulatory hurdles and competitive entry barriers in new markets, which are not yet quantified in disclosed guidance.

📋 Recent Filings

🧠 Analyst's Read

CORONA Remedies is executing a clear growth strategy anchored in product diversification, geographic expansion, and operational excellence, supported by strong financial metrics and governance discipline. Investors should monitor execution progress in international markets and the sustainability of margin performance amid competitive dynamics, particularly in high-growth therapeutic segments.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on CORONA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-03.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CORONA files new disclosures

Track CORONA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CORONA — Free

Free account · 2 AI queries/day